Generation of therapeutic T cells from human induced pluripotent stem cells.
Level 5 - mechanism / opinion, no new human data
Narrative review describing preclinical bench methodology and technological developments
PubMed 42216053 · doi:10.1186/s41232-026-00425-5
What was done
This narrative review describes a research platform for deriving "rejuvenated" therapeutic T cells and regulatory T cells from human induced pluripotent stem cells (iPSCs). It outlines the technological shift from autologous approaches to allogeneic off-the-shelf strategies, including clinical-grade xeno-free manufacturing, synthetic receptor optimization, and gene editing aimed at reducing immunogenicity, enhancing signaling, and preventing Graft-versus-Host Disease (GvHD).
What was found
The abstract reports no numerical findings or statistical measures. It summarizes methodological progress in generating effector and regulatory T cells from iPSCs and outlines ongoing translational hurdles.
Why it matters
Generating off-the-shelf T cells from iPSCs could overcome patient-derived T-cell exhaustion and supply bottlenecks in cell therapies for cancer, chronic infections, and autoimmune diseases.
Limits
This is a narrative review with no primary experimental dataset, sample size, or clinical trial outcomes reported in the abstract. Real-world efficacy, safety, and long-term durability in human patients remain unmeasured.
Cited by
- supports Induced pluripotent stem cells (iPSCs) can be differentiated into functional T cells.